Izotropic Corporation

OTC: IZOZF · Healthcare · Medical - Diagnostics & Research

Canadian filerHQ Surrey, BCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 13DQ —GM —SS 30

v0.1 · 35/100 weight · pillars only

↑ disclosure history, market scale · ↓ return on assets, balance-sheet leverage

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.3M

Employees

Market cap

$13.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$2.3M-3.1M CAD2025

Operating income-$1.5M-2.1M CAD2025

Total assets$300.3k414.7k CAD2025

Liabilities$3.8M5.3M CAD2025

Equity-$3.5M-4.9M CAD2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Izotropic Corporation booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Bionano Genomics, Inc.47D Aurora Spine Corporation65B Pharma-Bio Serv, Inc.58C Inhibitor Therapeutics, Inc.29D

Key facts

CEORobert Louis Thast

SectorHealthcare

IndustryMedical - Diagnostics & Research

HeadquartersSurrey, BC

ExchangeOTC: IZOZF

Employees5

IPO date2021-01-08

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.